Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Genmab ( (GMAB) ) has issued an update. Genmab reported first-quarter 2026 results on May 7, 2026, with revenue rising 25% year-on-year to $896 million, driven by higher royalties from DARZALEX and Kesimpta and increased net sales of its lymphoma drug EPKINLY, though operating profit slipped slightly to $180 million due to higher R&D, commercialization spend and Merus-related integration costs. The company highlighted U.S. FDA approval of a supplemental filing that removes the 24-hour hospitalization recommendation for third-line-plus relapsed/refractory DLBCL patients treated with EPKINLY, underscoring its push to integrate the Merus acquisition and invest in launch readiness for late-stage assets Rina-S and petosemtamab, while maintaining its full-year 2026 financial guidance. Genmab’s expanding royalty base and growing direct product sales underpin its strategy to transition further into a commercial-stage oncology player, even as integration charges and intangible amortization from the Merus deal weigh on near-term profitability. The first-quarter performance, including continued investment in its global commercialization infrastructure and late-stage pipeline, positions the company for potential upcoming launches that could strengthen its competitive standing in antibody therapeutics and offer additional value for partners and shareholders. The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page. Spark’s Take on GMAB Stock According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral. The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings. To see Spark’s full report on GMAB stock, click here. More about Genmab Genmab A/S is a Denmark-based biotechnology company specializing in the development and commercialization of antibody-based therapies for cancer and other serious diseases. The company generates substantial royalty revenue through partnerships, notably with Johnson & Johnson for multiple myeloma drug DARZALEX and with Novartis for multiple sclerosis therapy Kesimpta, while expanding a late-stage portfolio that includes EPKINLY, Rina-S and petosemtamab. Average Trading Volume: 1,621,965 Technical Sentiment Signal: Sell Current Market Cap: $16.62B Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.